These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 33431159)

  • 21. Vaccine profile of 4CMenB: a four-component Neisseria meningitidis serogroup B vaccine.
    Esposito S; Principi N
    Expert Rev Vaccines; 2014 Feb; 13(2):193-202. PubMed ID: 24393061
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modelling the impact of 4CMenB and MenACWY meningococcal combined vaccination strategies including potential 4CMenB cross-protection: An application to England.
    Beck E; Klint J; Garcia S; Abbing V; Abitbol V; Akerborg O; Argante L; Bekkat-Berkani R; Hogea C; Neine M; Vadivelu K; Whelan J; Meszaros K
    Vaccine; 2020 Nov; 38(47):7558-7568. PubMed ID: 32807531
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epidemiological impact and cost-effectiveness of introducing vaccination against serogroup B meningococcal disease in France.
    Lecocq H; Parent du Châtelet I; Taha MK; Lévy-Bruhl D; Dervaux B
    Vaccine; 2016 Apr; 34(19):2240-50. PubMed ID: 27002504
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact.
    Christensen H; Hickman M; Edmunds WJ; Trotter CL
    Vaccine; 2013 May; 31(23):2638-46. PubMed ID: 23566946
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study.
    Parikh SR; Andrews NJ; Beebeejaun K; Campbell H; Ribeiro S; Ward C; White JM; Borrow R; Ramsay ME; Ladhani SN
    Lancet; 2016 Dec; 388(10061):2775-2782. PubMed ID: 28100432
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Meningococcal Serogroup B Disease in Vaccinated Children.
    Soler-Garcia A; Fernández de Sevilla M; Abad R; Esteva C; Alsina L; Vázquez J; Muñoz-Almagro C; Noguera-Julian A
    J Pediatric Infect Dis Soc; 2020 Sep; 9(4):454-459. PubMed ID: 31634404
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Introduction of a second MenB vaccine into Europe - needs and opportunities for public health.
    Findlow J; Nuttens C; Kriz P
    Expert Rev Vaccines; 2019 Mar; 18(3):225-239. PubMed ID: 30821535
    [TBL] [Abstract][Full Text] [Related]  

  • 28. First statewide meningococcal B vaccine program in infants, children and adolescents: evidence for implementation in South Australia.
    Marshall HS; Lally N; Flood L; Phillips P
    Med J Aust; 2020 Feb; 212(2):89-93. PubMed ID: 31909501
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vaccinating Italian infants with a new multicomponent vaccine (Bexsero®) against meningococcal B disease: A cost-effectiveness analysis.
    Gasparini R; Landa P; Amicizia D; Icardi G; Ricciardi W; de Waure C; Tanfani E; Bonanni P; Lucioni C; Testi A; Panatto D
    Hum Vaccin Immunother; 2016 Aug; 12(8):2148-2161. PubMed ID: 27163398
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-Effectiveness of Meningococcal Vaccination Among Men Who Have Sex With Men in New York City.
    Simon MS; Weiss D; Geevarughese A; Kratz MM; Cutler B; Gulick RM; Zucker JR; Varma JK; Schackman BR
    J Acquir Immune Defic Syndr; 2016 Feb; 71(2):146-54. PubMed ID: 26334735
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness analysis of a multicomponent meningococcal serogroup B vaccine in hypothetic epidemic situation in a middle-income country.
    Izquierdo G; Torres JP; Santolaya ME; Valenzuela MT; Vega J; Chomali M
    Hum Vaccin Immunother; 2015; 11(4):875-83. PubMed ID: 25714390
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-world implementation of 4-component meningococcal serogroup B vaccine (4CMenB): implications for clinical practices.
    Sohn WY; Tahrat H; Novy P; Bekkat-Berkani R
    Expert Rev Vaccines; 2022 Mar; 21(3):325-335. PubMed ID: 35068299
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comprehensive review of clinical and real-world safety data for the four-component serogroup B meningococcal vaccine (4CMenB).
    Marshall GS; Abbing-Karahagopian V; Marshall HS; Cenci S; Conway JH; Occhipinti E; Bekkat-Berkani R; Banzhoff A; Sohn WY
    Expert Rev Vaccines; 2023; 22(1):530-544. PubMed ID: 37278390
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Health impact and cost-effectiveness of introducing the vaccine (Bexsero) against MenB disease into the Brazilian immunization programme.
    Moura Silveira M; McBride AJA; Trotter CL
    Vaccine; 2019 Oct; 37(45):6783-6786. PubMed ID: 31570182
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High coverage of diverse invasive meningococcal serogroup B strains by the 4-component vaccine 4CMenB in Australia, 2007-2011: Concordant predictions between MATS and genetic MATS.
    Tozer SJ; Smith HV; Whiley DM; Borrow R; Boccadifuoco G; Medini D; Serruto D; Giuliani MM; Stella M; De Paola R; Muzzi A; Pizza M; Sloots TP; Nissen MD
    Hum Vaccin Immunother; 2021 Sep; 17(9):3230-3238. PubMed ID: 33847225
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A review of the immunogenicity, safety and current recommendations for the meningococcal serogroup B vaccine, MenB-FHbp.
    Burman C; Alderfer J; Snow VT
    J Clin Pharm Ther; 2020 Apr; 45(2):270-281. PubMed ID: 31820483
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Methods to evaluate serogroup B meningococcal vaccines: From predictions to real-world evidence.
    Borrow R; Taha MK; Giuliani MM; Pizza M; Banzhoff A; Bekkat-Berkani R
    J Infect; 2020 Dec; 81(6):862-872. PubMed ID: 32745637
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The cost-of-illness for invasive meningococcal disease caused by serogroup B Neisseria meningitidis (MenB) in Germany.
    Scholz S; Koerber F; Meszaros K; Fassbender RM; Ultsch B; Welte RR; Greiner W
    Vaccine; 2019 Mar; 37(12):1692-1701. PubMed ID: 30661834
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modelling the cost-effectiveness of catch-up 'MenB' (Bexsero) vaccination in England.
    Christensen H; Trotter CL
    Vaccine; 2017 Jan; 35(2):208-211. PubMed ID: 27923519
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Meningococcal B vaccine (4CMenB): the journey from research to real world experience.
    Rappuoli R; Pizza M; Masignani V; Vadivelu K
    Expert Rev Vaccines; 2018 Dec; 17(12):1111-1121. PubMed ID: 30457407
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.